ConvaTec Group/£CTEC

08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX

About ConvaTec Group

Ticker

£CTEC
Sector

Primary listing

LSE

Employees

10,000

ConvaTec Group Metrics

BasicAdvanced
£5B
31.27
£0.08
0.77
£0.05
2.02%

What the Analysts think about ConvaTec Group

Analyst ratings (Buy, Hold, Sell) for ConvaTec Group stock.

Bulls say / Bears say

On August 20, 2025, ConvaTec announced a $300 million share buyback to be conducted through the end of 2025. The news boosted shares by 7% and demonstrates ConvaTec’s strong cash flow and ongoing commitment to shareholder returns (Proactive Investors).
In its H1 2025 results published July 29, 2025, ConvaTec reported $1.18 billion in revenue (up 6%), adjusted EPS up 18.7% to 8 cents, and an adjusted operating margin expansion of 130 bps to 21.3%, surpassing analyst expectations (Investing.com).
On May 22, 2025, ConvaTec raised its full-year 2025 organic revenue growth guidance to 5.5–7.0% (excluding InnovaMatrix), up from 5.0–7.0%. The company also maintained its 22.0–22.5% adjusted operating margin target, reflecting management’s confidence in broad-based growth (Investing.com).
CEO Karim Bitar’s medical leave announced on August 4, 2025 led the CFO and Financial Controller to step in as interim CEO and CFO, respectively. This raised concerns about strategic continuity and caused shares to fall 1% on the news (Investing.com).
ConvaTec warned on July 15, 2025 that a draft payment proposal from CMS (Centers for Medicare & Medicaid Services) regarding skin substitutes could reduce reimbursement rates, creating a 1–2% headwind to fiscal 2026 revenue. This may also limit market access for InnovaMatrix, which represents roughly 3% of group revenue (Investing.com).
At the AGM on May 22, 2025, 32.96% of shareholders voted against the proposed Directors’ Remuneration Policy and 24.36% opposed the Omnibus Incentive Plan, highlighting considerable investor dissatisfaction with executive compensation (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.

ConvaTec Group Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ConvaTec Group Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy £CTEC

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs